The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comprehensive genomic profiling of advanced anal adenocarcinoma.
 
Nozomu Ogura
No Relationships to Disclose
 
Hidekazu Hirano
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Fujifilm; Novartis; Taiho Pharmaceutical; Teijin Pharma
Research Funding - BeiGene (Inst)
 
Kouya Shiraishi
No Relationships to Disclose
 
Hiroyuki Fujii
No Relationships to Disclose
 
Toshiharu Hirose
No Relationships to Disclose
 
Hirokazu Shoji
Research Funding - Amgen (Inst); Astellas Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)
 
Natsuko Tsuda Okita
No Relationships to Disclose
 
Atsuo Takashima
Honoraria - Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Amgen - Local PI (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Merck Sharp & Dohme (Inst); Ono Pharmaceutical (Inst)
 
Takafumi Koyama
Honoraria - Chugai Pharma; Sysmex
Consulting or Advisory Role - Amgen
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo RD Novare (Inst); Lilly (Inst); Novartis (Inst); PACT Pharma (Inst); Pfizer (Inst); Takeda (Inst); Zymeworks (Inst)
 
Ken Kato
Honoraria - BMS; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - Bayer; BeiGene; MSD; Oncolys BioPharma; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Chugai Pharma (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)